Related Experiment Video
Updated: Aug 16, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
[Dosage of inactivated influenza vaccine for infants]
Daisuke Tamura1, Takuma Miura, Ritei Uehara
1Department of Pediatrics, Jichi Medical School.
Insights
Infants under one year old showed lower protective antibody responses to inactivated influenza vaccines compared to older children. Increasing the vaccine dosage for infants is recommended to achieve protective antibody levels.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Immunology
Context:
- The standard inactivated influenza vaccine dosage for infants under one year old in Japan is 0.1 mL.
- This dosage is half that administered in Europe and the USA.
- Lower vaccine efficacy in infants may be linked to the reduced dosage.
Purpose:
- To investigate the hypothesis that a lower dosage of inactivated influenza vaccine contributes to reduced efficacy in infants under one year old.
- To compare the immunogenicity of inactivated influenza vaccine in infants (8-11 months) versus older children (12-16 months).
Summary:
- A prospective study compared antibody titers after two doses of inactivated influenza vaccine in two age groups: infants (0.1 mL dose) and children over one year (0.2 mL dose).
- Infants demonstrated significantly lower proportions of protective hemagglutinin inhibiting antibody titers and fewer four-fold increases in antibodies across all tested strains (A/H1N1, A/H3N2, B) compared to older children.
- Mean antibody titers were also significantly lower in infants than in the older children's group.
Impact:
- Findings suggest that the lower inactivated influenza vaccine dosage in infants is associated with diminished antibody responses.
- Results support the need for adequate vaccine dosage to achieve protective antibody levels in infants.
- This research could inform revised vaccination guidelines for infants to improve influenza protection.
Background:
In Japan, the inoculation dosage of inactivated influenza vaccine for children under 1 year old is 0.1 mL per dose. The dosage is not half as much as that in Europe and the U.S.A. We considered that low efficacy fate of influenza vaccine in children under 1 year old results from its less dosage. So we designed this study to verify this hypothesis.
Materials And Methods:
This study was prospective in design. Subjects were divided into two groups by age: 8 to 11 months old (n = 26) and 12 to 16 months old (n = 22). Infants received 0.1 mL of inactivated influenza vaccine and over 1 year, 0.2 mL. Forty-eight children were inoculated twice at intervals of over 4 weeks. Serum samples were drawn before the first inoculation and 1 month after the second vaccination. Pre- and post-immunization antibody titers were measured. The titers of hemaglutinatinin inhibiting antibodies to the 3 viral strains were assayed. Antibody titers were determined using HAI.
Results:
The post-vaccination proportions of children with protective HAI antibody titers were significantly smaller in infants than those in children over 1 year old (A/H1N1; 23% vs. 77%, A/H3N2; 39% vs. 73%, B; 0% vs. 32%). The number of children with >four-fold increased antibodies were significantly smaller in infants than that in 1 year old (A/H1N1; 74% vs. 91%, B; 0% vs. 39%). In the mean antibody titer, there were signficant differences between infants and children over 1 year old (A/H1N1; 19 times vs. 56 times, B; 8 times vs. 14 times).
Conclusion:
We consider that significant differences in antibody titers between infants and children over 1 year old were caused by the difference of dosage in influenza vaccines. To obtain protective levels of antibodies by influenza vaccines in infants, they must be inoculated with enough dosage.
More Related Videos
Related Concept Videos
Drug Dosing: Infants and Children
Influenza
IV Infusion to Oral Dosing: Conversion Methods
Vaccinations
Development of Immunocompetence
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

